NanoViricides, Inc. (the “Company”) reported today that Milton Boniuk, MD, the Caroline F. Elles Chair Professor of Ophthalmology at Baylor College of Medicine, and a Director of the Company, has invested $5M in the Company in the form of a convertible debenture (the “Debenture”).
GS Venture, GS Group holding corporate venture fund, together with LLC “Carbon nanostructured materials”, being a part of the holding, has announced a competition among venture projects, research and business...
mCube, provider of the world’s smallest MEMS motion sensors, today announced it has closed a $37 million Series C financing round.
Under the terms of the agreement, Oasmia will initially perform tests to investigate the possibility of making a solid formulation with the partner's specified compound in combination with XR-17. XR-17 has been proven in several pre-clinical and clinical studies to make single or multiple APIs (Active Pharmaceutical Ingredients) water-soluble.
Celsion Corporation (Celsion), an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases.
memsstar Limited, a leading provider of etch and deposition equipment and technology solutions to manufacturers of semiconductors and micro-electrical mechanical systems (MEMS), today announced that it has relocated to a new, larger facility.
AuraSense Therapeutics, a Chicago-based biopharmaceutical company commercializing spherical nucleic acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, has announced the close of its Series C financing that included an investment by Bill Gates.
OCSiAl, the leading technology manufacturer for the mass industrial production of graphene tubes, announced today at a press conference at the TechConnect World Innovation Conference that it has acquired Zyvex Technologi...
Today, Thomas Swan announced plans to bring forward the scale-up of their Elicarb® Graphene products. Originally scheduled for year-end 2014, the first integrated kg/day process will now be completed by September 2014.
Avidity NanoMedicines LLC, a biopharmaceutical company pioneering a breakthrough approach to the targeted delivery of nucleic acid-based medicines, announced today that its scientific co-founder, Mark E. Davis, Ph.D., will receive the 2014 Prince of Asturias Award for Technical and Scientific Research.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.